Literature DB >> 35035761

Clinical characteristics and prediction analysis of the recovered COVID-19 patients with re-detectable positive RNA test.

Qi Li1,2, Li Shuai3, Li Tan1,2, Lijun Song1,2, Chongyang Ou4,5, Xiaocheng Song4,5, Jian He6,7, Ming Gao7,8, Xinyu Hu1,2, Yang Liu9, Hui Chen10, Zui Zou2,9,11, Chao Yu4,5, Baodong Qin12, Wenyun Xu9.   

Abstract

BACKGROUND: Previous studies have unveiled the occurrence of re-detectable positive (RP) RNA test result after hospital discharge among recovered COVID-19 patients, but the clinical characteristics of RP patients (RP patients) and the potential features affecting RP RNA test outcome remain unclear.
METHODS: A total of 742 COVID-19 patients discharged between March 1st, 2020 and March 20th, 2020 were enrolled. All patients were followed-up for SARS-CoV-2 RNA test and RP patents were identified. The clinical characteristics between RP patients and NRP patients were compared, and the potential features affecting re-detectable RNA test outcome were further evaluated.
RESULTS: Up to April 9th, 2020, 60 recovered patients (8.09%) had been re-detected to be SARS-CoV-2 RNA positive. Among those 60 RP patients, the median RP time was 12 days from the last negative result of SARS-CoV-2 RNA test or 10 days from hospital discharge. RP patients were prone to be older, having mild/moderate conditions, unilateral lung involvement and fatigue, chills, stuffy or runny nose, with high lymphocyte count. Multivariate logistic analysis and COX regression analysis demonstrated that age, lymphocyte count, urea nitrogen, stuffy or runny nose as well as lung involvement were independently associated with RP RNA test (P<0.05).
CONCLUSIONS: Older patients accompanied with stuffy or runny nose, low urea nitrogen as well as unilateral lung involvement were more likely to develop RP RNA test result after hospital discharge. Therefore, we strongly suggest using broncho-alveolar lavage fluid for RNA detection, extending quarantine time, and conducting continual follow-up medical examination for those discharged patients. AJTR
Copyright © 2021.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; patients; positive RNA test; re-detectable

Year:  2021        PMID: 35035761      PMCID: PMC8748099     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  23 in total

1.  Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-03-12

2.  SARS-CoV-2 presented in the air of an intensive care unit (ICU).

Authors:  Tingxu Jin; Jun Li; Jun Yang; Jiawei Li; Feng Hong; Hai Long; Qihong Deng; Yong Qin; Jiajun Jiang; Xuan Zhou; Qian Song; Chunliu Pan; Peng Luo
Journal:  Sustain Cities Soc       Date:  2020-08-15       Impact factor: 7.587

3.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

4.  Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient.

Authors:  Xiao-Hong Yao; Zhi-Cheng He; Ting-Yuan Li; Hua-Rong Zhang; Yan Wang; Huaming Mou; Qiaonan Guo; Shi-Cang Yu; Yanqing Ding; Xindong Liu; Yi-Fang Ping; Xiu-Wu Bian
Journal:  Cell Res       Date:  2020-04-28       Impact factor: 25.617

5.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

6.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.

Authors:  Chih-Cheng Lai; Tzu-Ping Shih; Wen-Chien Ko; Hung-Jen Tang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2020-02-17       Impact factor: 5.283

7.  Liver injury in COVID-19: management and challenges.

Authors:  Chao Zhang; Lei Shi; Fu-Sheng Wang
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-04

8.  Prolonged presence of SARS-CoV-2 viral RNA in faecal samples.

Authors:  Yongjian Wu; Cheng Guo; Lantian Tang; Zhongsi Hong; Jianhui Zhou; Xin Dong; Huan Yin; Qiang Xiao; Yanping Tang; Xiujuan Qu; Liangjian Kuang; Xiaomin Fang; Nischay Mishra; Jiahai Lu; Hong Shan; Guanmin Jiang; Xi Huang
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-20

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.

Authors:  Dasheng Li; Dawei Wang; Jianping Dong; Nana Wang; He Huang; Haiwang Xu; Chen Xia
Journal:  Korean J Radiol       Date:  2020-03-05       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.